Q1 Recalls Snapshot: It’s A Mixed Bag As Device Recalls Fall 10% But Recalled Units Rise 3%

 
• By Shawn M. Schmitt

Recalls initiated by the medical device industry were relatively stable in the first quarter of 2021 as companies recalled 212 products, a 10% decrease from the previous quarter. Check out our Q1 recalls infographic for more.

Q1 Device Recalls

Medical device recalls were relatively stable in the first quarter of 2021. Manufacturers recalled 212 products, a noteworthy 10% drop from Q4 2020, when there were 235 corrections and removals. Meanwhile, the number of recalled units increased slightly in Q1, to 60,768,817. That’s 3% higher than in Q4, when 59,314,216 units were recalled, and marks the most units recalled since Q1 2020. In announcing its most recent quarterly recalls index, Sedgwick Brand Protection noted that one recall of gowns accounted for 29 million of the recalled units.

Informa Pharma Intelligence

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

More from Policy & Regulation

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?